INTRODUCTION
• Allergic rhinitis (AR) is a chronic disease of the upper respiratory tract caused by exposure to allergens inducing inflammation of the nasal mucosa and of the conjunctiva mediated by antibody Immunoglobulin E (IgE).
•According to local literature, prevalence of symptomatic AR is around 20% and grass pollen is the most common allergen causing AR in Turkey. 5% of these patients suffer from moderate and severe AR still remain uncontrolled despite symptomatic treatment (Cingi, C et al, (2010) , 'Prevalence of allergic rhinitis among the adult population in Turkey', , Ait-Khaled, N et al, (2009) ', Allergy, •Allergen-specific immunotherapy (AIT) is recommended as a second line treatment for patients with moderate to severe allergic rhinitis not or poorly controlled by symptomatic treatments.
•The Five Grass Pollen Sublingual Tablet (5GPST) is an alternative AIT in Turkey.
OBJECTIVE
• The aim of this budget impact model (BIM) was to assess the cost saving potential of the 5GPST in the Turkish reimbursement system.
METHODOLOGY
•Cost calculations were made from the payer perspective as per the guidelines of the Social Security Institution (SSI).
•The time horizon considered in the model was one year.
•Only direct medical costs were included. 
INPUTS OF THE MODEL

RESULTS
•Total cost of AR treatment for a patient treated with symptomatic treatment alone was 373 TL per year and reached to 1.607 TL per year for patients receiving subcutaneous immunotherapy.
•Annual total cost of AR per patient with 5GPST with %11 discount for the first reimbursement year is 1.168 TL. Total yearly cost of AR with 5GPST with % 41 discount is 864 TL.
CONCLUSION
• In Turkey, compared to subcutaneous AIT, 5GPST is a cost saving alternative for treatment of patients with moderate to severe seasonal AR uncontrolled or not properly controlled by symptomatic treatments, from the SSI perspective.
•The treatment is 27% or 46% cheaper with 5GPST with 11% or 41% discount rates respectively. 
